Keros Therapeutics

Q2 FY2026 EarningsQ2 FY2026 results showed a net loss of $28.7M, slightly beating the consensus loss estimate of $26.8M, driven by significant R&D and G&A cost reductions following the 2025 corporate restructuring. Total revenue was $0, missing the consensus estimate of $0.71M, as license revenue from the Takeda agreement was fully recognized in the prior year. EPS GAAP loss of $1.45 per share was worse than the consensus of $1.34, primarily due to a lower-than-expected weighted average share count. The company initiated Phase 2 trials for rinvatercept in DMD and confirmed a cash runway extending into the first half of 2028.